Brainstorm Cell Therapeutics (NASDAQ:BCLI) Research Coverage Started at StockNews.com
StockNews.com assumed coverage on shares of Brainstorm Cell Therapeutics (NASDAQ:BCLI – Free Report) in a research note published on Thursday. The firm issued a hold rating on the biotechnology company’s stock. Separately, Maxim Group cut Brainstorm Cell Therapeutics from a buy rating to a hold rating in a research report on Thursday, September 28th. Get […]
More Stories
Short Interest in Cornerstone Total Return Fund, Inc. (NYSEAMERICAN:CRF) Decreases By 12.6%
Cornerstone Total Return Fund, Inc. (NYSEAMERICAN:CRF – Get Free Report) was the target of a significant decline in short interest...
Idaho Strategic Resources, Inc. (NYSEAMERICAN:IDR) Short Interest Update
Idaho Strategic Resources, Inc. (NYSEAMERICAN:IDR – Get Free Report) was the recipient of a large increase in short interest in...
Becton, Dickinson and Company (NYSE:BDX) Short Interest Update
Becton, Dickinson and Company (NYSE:BDX – Get Free Report) was the recipient of a significant decline in short interest in...
Calamos Convertible Opportunities and Income Fund (NASDAQ:CHI) Short Interest Update
Calamos Convertible Opportunities and Income Fund (NASDAQ:CHI – Get Free Report) was the recipient of a significant decrease in short...
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Sees Large Increase in Short Interest
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN – Get Free Report) was the recipient of a large increase in short interest in...
AECOM (NYSE:ACM) Releases FY 2025 Earnings Guidance
AECOM (NYSE:ACM – Get Free Report) issued an update on its FY 2025 earnings guidance on Monday morning. The company...